Table 2.

Summary of STAT3 inhibitors in clinical trials.

Inhibitors	Target	NCT Number	Conditions	Phase	Reference
STAT3 DECOY	STAT3	NCT00696176	Head and neck cancer	Phase I	[151]
Pyrimethamine	STAT3	NCT01066663	Chronic lymphocytic leukemia	Phase II	[152]
Tipifarnib	STAT3	NCT00049114	IIB-IIIC breast cancer	Phase II	[153]
OPB-31121	STAT3	NCT00657176	Solid tumor	Phase I	[154]
		NCT00955812	Solid tumor	Phase I	[155]
Danvatirsen	STAT3	NCT02549651	Relapsed or refractory diffuse large B-cell lymphoma	Phase I	[156]
MSC-1 (AZD0171)	STAT3	NCT03490669	Advanced solid tumors	Phase I	[157]
OPB-51602	STAT3	NCT01184807	Solid malignancies	Phase I	[158]
AZD9150	STAT3	NCT01563302	Lymphoma	Phase I	[112]
WP1066	STAT3	NCT02977780	Recurrent malignant glioma	Phase I	[159]
Erlotinib	EGFR	NCT00779389	Head and neck cancer	Phase I	[160]
Napabucasin	STAT3	NCT01830621	Advanced colorectal cancer	Phase III	[161]
Napabucasin	STAT3	NCT02753127)	Metastatic colorectal cancer	Phase I	[162]
OPB-111077	STAT3	NCT01942083	Advanced hepatocellular carcinoma	Phase I	[163]
		NCT01711034	Advanced cancer	Phase I	[164]
Ruxolitinib	JAK1/2	NCT02041429	HER2-negative metastatic breast cancer	Phase I	[165]
		NCT02145637	Non-small cell lung cancer	Phase I	[166]
		NCT02015208	Chronic lymphocytic leukemia	Phase II	[167]
		NCT02066532	Metastatic HER2 positive breast cancer	Phase I II	[168]
		NCT00674479	Postmyeloproliferative neoplasm acute myeloid leukemia	Phase II	[169]
		NCT01702064	Chronic myeloid leukemia	Phase I	[170]
AZD1480	JAK2	NCT01112397	Solid tumor	Phase I	[171]
CEP-701	JAK2	NCT00494585	Primary or post-polycythemia vera/essential thrombocythemia myelofibrosis	Phase II	[172]
Afatinib	EGFR	NCT02145637	EGFR mutant NSCLC	Phase I	[166]
Nilotinib	EGFR	NCT01168050	KIT-Altered Melanoma	Phase II	[173]
nilotinib	EGFR	NCT01061177	Chronic myeloid leukemia	Phase III	[174]